The flow cytometry analysis using Annexin V/PI showed that the KS18 therapy (5 μM for 24 h) had a significant impact on MM patient samples, leading to a high rate of apoptosis 88.8%, as shown in Figure 4C. The gene discussed is ANXA5; the disease is Miyoshi myopathy.